JANUX THERAPEUTICS INC

JANXNASDAQ

🏆 #2040 by market capEarnings Nov 5US Equity

$16.52▲ $0.11 (+0.67%)

🌙 After hours$16.52▲ 0.00%Regular close · extended-hours price shown

1h—

24h▲ 0.7%

7d▲ 3.2%

14d▲ 10.4%

30d▲ 2.4%

1y▼ 31.9%

🏦Market Cap

$1.01B

Small Cap

📈Revenue Growth (YoY)

+5367.0%

High Growth

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

41.8x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $16.43 – $16.65
52-Week Range: $12.12 – $35.34
Volume: $2.11B
Avg Volume: $1.45B
Shares Outstanding: 61.0M
Next Earnings: Oct 7, 2026

Fundamentals Snapshot

Annual Revenue: $10M
Last Q Revenue: $10M
P/E Ratio: —
P/S Ratio: 41.8x
EPS (TTM): $-1.64
Dividend Yield: —

Why Investors Own JANX

✓High-growth profile — revenue up -4.2% YoY with expanding US Equity exposure.
✓Healthy economics — 46% gross margin and 16% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$10M▼ −5.4% YoY

Gross Margin (TTM)

45.9%▲ +4.3% YoY

Operating Income (TTM)

$3M▼ −5.4% YoY

Free Cash Flow (TTM)

$2M▼ −5.4% YoY

About JANUX THERAPEUTICS INC

Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.

🦦